411: Capricor's data clash and a fugitive in the C-suite

Sarepta Therapeutics transitions to new CEO Michael Severino, marking a shift after nearly a decade under Doug Ingram, while GSK initiates a $2.5 billion cost-cutting plan to prioritize late-stage pipeline development. Regulatory scrutiny intensifies as an FDA advisory panel rejects Capricor Therapeutics’ Duchenne muscular dystrophy treatment, Daramiacel, citing concerns over statistical analysis plans and efficacy data. Simultaneously, the industry grapples with the revelation that fugitive Ronald Fisher operated as a biotech executive under the alias Richard Graydon for years, successfully securing high-level roles without undergoing rigorous credential verification. Amidst these developments, Anthony Fauci faced a contentious Senate hearing regarding COVID-19 origins. The episode concludes with the departure of long-time producer Hyacinth and the announcement of a summer hiatus for the program.